360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Meridian Bioscience Inc

Type: Company

Name: Meridian Bioscience Inc

First reported May 10 2013 - Updated May 10 2013 - 1 reports

Form 10-Q MERIDIAN BIOSCIENCE INC For: Mar 31

StreetInsider.com - Form 10-Q MERIDIAN BIOSCIENCE INC For: Mar 31 ... [Published Street Insider - May 10 2013]

Entities: Meridian Bioscience Inc, 10-q

First reported May 07 2013 - Updated May 07 2013 - 1 reports

Meridian Bioscience reports higher Q2 net earnings, provides outlook for 2013

Meridian Bioscience, Inc., a provider of diagnostic test kits, has reported that net earnings for the second quarter ended March 31, 2013 were $10.25 million, or $0.24 per diluted share, compared to $9.63 million, or $0.23 per diluted share, for the same ... [Published Individual.com - May 07 2013]

Entities: Meridian Bioscience Inc, Net Earnings, Clostridium Difficile, Meridian Life Science

First reported May 04 2013 - Updated May 04 2013 - 1 reports

Meridian Bioscience, Inc. (VIVO) - Product Pipeline Analysis, 2013 Update

SummaryMeridian Bioscience, Inc. (Meridian) is a fully integrated life science company. It undertakes the research, development, manufacture and distribution of a wide range of diagnostic test kits, purified reagents and related products. The company ... [Published Research and Markets - May 04 2013]

Entities: Meridian Bioscience Inc, Pipeline, Reagent

First reported May 03 2013 - Updated May 03 2013 - 1 reports

Form 4 MERIDIAN BIOSCIENCE INC For: May 01 Filed by: KRAEUTLER JOHN A

StreetInsider.com - Form 4 MERIDIAN BIOSCIENCE INC For: May 01 Filed by: KRAEUTLER JOHN A ... [Published Street Insider - May 03 2013]

Entities: Meridian Bioscience Inc

First reported May 03 2013 - Updated May 03 2013 - 1 reports

Meridian Bioscience In Retrospect: Shares Down 1.4% Since Downgraded One Week Ago (VIVO)

(Financial News Network On) Meridian Bioscience was downgraded from Buy to Hold by Craig-Hallum one week ago. The stock closed at $20.13, which is 1.4% lower than the price one week ago ($20.42). In the past 52 weeks, shares of Meridian Bioscience have ... [Published Individual.com - May 03 2013]

Entities: Meridian Bioscience Inc

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Standard & Poor's

Meridian Bioscience Makes a Move: Up 2.5%

(Financial News Network On) Up 2.5% to $20.01, Meridian Bioscience (NASDAQ:VIVO), is one of today's notable movers. The S&P is trading higher by 0.8% to 1,596 and the Dow is trading 0.7% higher to 14,812. Meridian Bioscience has overhead space with ... [Published Individual.com - May 02 2013]

Entities: Meridian Bioscience Inc, Standard & Poor's

First reported Apr 27 2013 - Updated Apr 27 2013 - 1 reports

Meridian Bioscience Stock Rating Lowered by Craig Hallum (VIVO)

Meridian Bioscience (NASDAQ: VIVO) Meridian Bioscience (NASDAQ: VIVO) traded down 4.02% on Friday, hitting $19.60. Meridian Bioscience has a 1-year low of $16.19 and a 1-year high of $23.05. The stock's 50-day moving average is currently $22.16. The company ... [Published American Banking News - Apr 27 2013]

Entities: Meridian Bioscience Inc, Dividend, Earnings Per Share

First reported Apr 27 2013 - Updated Apr 27 2013 - 1 reports

EARNINGS REPORTS

Profits up 6 percent for Meridian BioscienceA weak European economy slowed sales growth for Meridian Bioscience Inc., but the Newtown-based life sciences company still earned $10.2 million in the first three months of 2013.Meridian Biosciences profit ... [Published Cincinnati Enquirer - Apr 27 2013]

Entities: Meridian Bioscience Inc, NB&T Financial Group Inc, First Financial Bancorp, Respiratory Infections, Medical Equipment

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

Meridian Bioscience Earnings: Here’s Why Investors Don’t Like These Results

Meridian Bioscience Inc. ( NASDAQ:VIVO ) delivered a profit and met Wall Street’s expectations, AND came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares ... [Published Wall St. Cheat Sheet - Apr 25 2013]

Entities: Meridian Bioscience Inc, Clostridium Difficile, Meridian Life Science

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

Meridian Bioscience Plans Quarterly Dividend of $0.19 (VIVO)

Meridian Bioscience (NASDAQ:VIVO) announced a quarterly dividend on Thursday, April 25th, Stock Ratings Network reports. Stockholders of record on Saturday, May 4th will be paid a dividend of $0.19 per share on Tuesday, May 14th. This represents a $0.76 ... [Published American Banking News - Apr 25 2013]

Entities: Meridian Bioscience Inc, Dividend, Life Science, Dividend Yield

First reported Apr 24 2013 - Updated Apr 25 2013 - 2 reports

Meridian Bioscience Up 18.7% Since SmarTrend Uptrend Call (VIVO)

SmarTrend identified an Uptrend for Meridian Bioscience (NASDAQ:VIVO) on August 15th, 2012 at $18.23. In approximately 8 months, Meridian Bioscience has returned 18.74% as of today's recent price of $21.64.Meridian Bioscience share prices have moved between ... [Published Comtex SmarTrend - Apr 25 2013]

Entities: Meridian Bioscience Inc, Reagent, Respiratory Infections, watchlist, gastrointestinal

First reported Apr 19 2013 - Updated Apr 19 2013 - 1 reports

Buyers Accumulate Shares of Meridian Bioscience, Up 3.1%

(Financial News Network On) Meridian Bioscience (NASDAQ:VIVO) is a company whose shares are active, trading 3.1% higher to $21.81. The Dow is down 0.3% to 14,499 and the S&P is currently up 0.5% to 1,550. Meridian Bioscience, Inc. manufactures, markets, ... [Published Individual.com - Apr 19 2013]

Entities: Meridian Bioscience Inc, Stocks, Standard & Poor's

Quotes

John A Kraeutler, CEO, said, "Flat sales growth, largely due to European weakness, was offset by second quarter earnings increasing by 6% as a result of excellent operating efficiency. USDx sales increased by 7%, driven primarily by increases in C difficile and foodborne test revenues. Due largely to continued weakness in European healthcare spending, our EURDx business unit reported sales down 12%. Meridian Life Science, which faced a record sales comparison in the year-ago period, reported revenues that were down by 8%. With respect to key diagnostic product categories, quarterly C difficile revenues increased 8% for USDx, but declined by 16% for EURDx. H pylori sales increased by 1% for USDx for the quarter, 7% for the first half of fiscal 2013; however, this category declined by 17% for the EURDx unit during the quarter. Foodborne test revenues grew 6% overall, 6% for USDx and 16% for EURDx."

Meridian Bioscience reports higher Q2 net earnings, provides outlook for 2013 [Published Individual.com - May 07 2013]

More Content

sort by: Date \| Relevance
10 Hot Healthcare Dogs Probe 6% To 38.2% Gains ... [Published Seeking Alpha - May 13 2013]
Form 10-Q MERIDIAN BIOSCIENCE INC For: Mar 31 [Published Street Insider - May 10 2013]
Top insider trades [Published Cincinnati Enquirer - May 10 2013]
Polar Cap Gbl Healthcare Growth&IT - Half Yearl... [Published Morningstar UK - May 09 2013]
Meridian Bioscience reports higher Q2 net earni... [Published Individual.com - May 07 2013]
9 Top Healthcare Dogs Hunt 3.5% To 51.9% Gains ... [Published Seeking Alpha - May 06 2013]
Meridian Bioscience, Inc. (VIVO) - Product Pipe... [Published Research and Markets - May 04 2013]
Friday 5/3 Insider Buying Report: HTCH, VIVO [Published Individual.com - May 03 2013]
Form 4 MERIDIAN BIOSCIENCE INC For: May 01 File... [Published Street Insider - May 03 2013]
Meridian Bioscience In Retrospect: Shares Down ... [Published Individual.com - May 03 2013]
Meridian Bioscience Makes a Move: Up 2.5% [Published Individual.com - May 02 2013]
Biotechnology Reagents Market By Technology, Ap... [Published TheStreet.com - Apr 30 2013]
Meridian Bioscience Shares Climbing Higher, Up ... [Published Individual.com - Apr 29 2013]
Top 3 Companies in the Health Care Supplies Ind... [Published Individual.com - Apr 29 2013]
1 Winner and 4 Losers from This Week’s Earnings... [Published Wall St. Cheat Sheet - Apr 28 2013]
1 Winner and 4 Losers from This Week’s Earnings... [Published Wall St. Cheat Sheet - Apr 28 2013]
Meridian Bioscience Stock Rating Lowered by Cra... [Published American Banking News - Apr 27 2013]
EARNINGS REPORTS [Published Cincinnati Enquirer - Apr 27 2013]
Meridian Bioscience Earnings: Here’s Why Invest... [Published Wall St. Cheat Sheet - Apr 25 2013]
Meridian Bioscience (VIVO): Q1 EPS of $0.24 in-... [Published Seeking Alpha - Apr 25 2013]
U.S./Canada daily earnings hits & misses April ... [Published Globe and Mail - Apr 25 2013]
U.S./Canada daily earnings hits & misses April ... [Published Globe and Mail - Apr 25 2013]
Meridian Bioscience Plans Quarterly Dividend of... [Published American Banking News - Apr 25 2013]
Meridian Bioscience Reports Second Quarter and ... [Published Business Wire Health News - Apr 25 2013]
Meridian Bioscience Up 18.7% Since SmarTrend Up... [Published Comtex SmarTrend - Apr 25 2013]
Gold Discovery in Timmins, Ontario by SGX Resou... [Published Zecco - Apr 24 2013]
Meridian Bioscience Up 18.7% Since SmarTrend Up... [Published Individual.com - Apr 24 2013]
5 Small Cap Dividend Stocks in Healthcare [Published Equities.com - Apr 23 2013]
Buyers Accumulate Shares of Meridian Bioscience... [Published Individual.com - Apr 19 2013]
Meridian Bioscience Announces illumigeneÂ® Grou... [Published Advance for Administrators of the Laboratory - Apr 19 2013]

Blogs

sort by: Date \| Relevance
1 Winner and 4 Losers from This Week’s Earnings... [Published Wall St. Cheat Sheet - Apr 28 2013] IPC The Hospitalist Company, Inc. ( NASDAQ:IPCM ) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. Adjusted Earnings Per Share increased 14% to $0.57 in the quarter versus EPS of $0.50 in the year-earlier quarter. ...
1 Winner and 4 Losers from This Week’s Earnings... [Published Wall St. Cheat Sheet - Apr 28 2013] IPC The Hospitalist Company, Inc. ( NASDAQ:IPCM ) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. Adjusted Earnings Per Share increased 14% to $0.57 in the quarter versus EPS of $0.50 in the year-earlier quarter. ...
Meridian Bioscience Earnings: Here’s Why Invest... [Published Wall St. Cheat Sheet - Apr 25 2013] Meridian Bioscience Inc. ( NASDAQ:VIVO ) delivered a profit and met Wall Street’s expectations, AND came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares ...
TravelCenters Of America Profits Rise and 3 Sto... [Published Wall St. Cheat Sheet - Mar 19 2013] TravelCenters Of America ( AMEX:TA ): Closing price $9.01 TravelCenters has posted fourth quarter earnings of 8 cents, with consensus at 11 cents. Shares closed up 19.02 percent on Monday at $9.01, and have been traded in a 52-week range of $4.18 ...
Abercrombie & Fitch Risk/Reward Deemed Attracti... [Published Wall St. Cheat Sheet - Dec 17 2012] Walgreen Co. ( NYSE:WAG ) is predicted by SunTrust to show same-store-sales growth acceleration which should begin during January as a result of easier comps and recaptured business back from Express Scripts ( NASDAQ:ESRX ). The firm gives the stock ...

Press Releases

sort by: Date \| Relevance
Meridian Bioscience Reports Second Quarter and ... [Published Business Wire Health News - Apr 25 2013]
Meridian Bioscience Recognized by Forbes as One... [Published Business Wire Professional Services News - Mar 28 2013]
Meridian Bioscience Recognized by Forbes as One... [Published Business Wire Health News - Mar 28 2013]
Meridian Bioscience Announces illumigene® Group... [Published Business Wire Health News - Mar 18 2013]
Bioline Launches ISOLATE II, a Precious Find fo... [Published EON Health & Medicine - Feb 06 2013]